Alzheimer's Disease in 2026 — What We Know, Can Treat, and Still Can't

Photo: Marta Branco / Pexels
Disclaimer: This article is for educational purposes only and does not constitute medical advice. If you or someone you know is experiencing memory loss or cognitive changes, consult a qualified physician or neurologist for diagnosis and treatment options.
Alzheimer's Disease in 2026 — What We Finally Know, What We Can Treat, and What We Still Can't
Approximately 55 million people worldwide are living with dementia today, and Alzheimer's disease accounts for 60–70% of those cases (WHO, 2024). For decades, every drug trial failed. Then, between 2023 and 2025, two medications — lecanemab (Leqembi) and donanemab (Kisunla) — became the first treatments ever proven to slow the disease's progression, not just manage symptoms. This guide explains what changed, what we now know about the biology, and what science is still struggling to answer.
What Alzheimer's Actually Does to the Brain
Alzheimer's disease is a progressive neurodegenerative disorder in which abnormal protein deposits destroy the brain's structure, function, and connectivity over years or decades before any symptoms appear.
Neurodegenerative disorder — a condition in which nerve cells progressively lose structure and function, eventually dying, causing irreversible cognitive and behavioral decline.
The damage follows a predictable anatomical path. It typically begins in the entorhinal cortex and hippocampus — regions responsible for forming new memories — before spreading outward to the neocortex, which governs language, reasoning, and personality. By the time a patient receives a clinical diagnosis, they may have already lost 20–30% of the neurons in affected regions (Alzheimer's Association, 2024).
Two protein abnormalities define the disease at the cellular level:
- Amyloid-beta — a short peptide fragment cleaved from a larger protein called APP (amyloid precursor protein). In healthy brains, amyloid-beta is cleared routinely. In Alzheimer's, it misfolds and clumps into plaques — sticky deposits that accumulate between neurons, triggering inflammation and disrupting synaptic communication.
- Tau — a protein that normally stabilizes microtubules, the internal transport rails of neurons. In Alzheimer's, tau becomes hyperphosphorylated, detaches from microtubules, and collapses into neurofibrillary tangles inside the cell body, strangling the neuron from within.
Neither plaques nor tangles appear overnight. Amyloid begins accumulating 15–20 years before the first memory complaint, according to longitudinal studies from the ADNI (Alzheimer's Disease Neuroimaging Initiative). Tau pathology follows later, correlating more closely with symptom severity than amyloid burden does — a distinction that has become clinically important.
The brain responds to this slow assault with chronic neuroinflammation. Microglia — the brain's immune cells — are recruited to clear plaques but, when overwhelmed, release inflammatory cytokines that accelerate neuronal death. Understanding these mechanisms is central to how neurotransmitters like acetylcholine are depleted in Alzheimer's: cholinergic neurons are disproportionately vulnerable, which is why early drugs targeted this system.
Brain volume loss is measurable by MRI within two to three years of symptom onset, and glucose metabolism — measured by PET scan — declines even earlier, giving researchers a window into presymptomatic disease.
The Amyloid Hypothesis and Its 30-Year Drama
The amyloid cascade hypothesis — first formally proposed by Hardy and Higgins in 1992 — holds that abnormal accumulation of amyloid-beta is the initiating event in Alzheimer's and that clearing it should halt or reverse the disease. For three decades, this hypothesis dominated research funding, clinical trial design, and pharmaceutical strategy.
It also failed repeatedly. Between 1998 and 2021, over 200 drug trials targeting Alzheimer's failed — a 99.6% attrition rate that was, at the time, the highest of any therapeutic area in medicine (Cummings et al., 2019, Alzheimer's Research and Therapy). Drugs that aggressively removed amyloid — like solanezumab and bapineuzumab — produced no cognitive benefit. The field fractured. Some researchers argued amyloid was a bystander, not a cause. Others contended the trials enrolled patients too late, when neurons were already dead.
The answer turned out to be: both criticisms were partially correct, and the hypothesis itself is not wrong — but incomplete.
Why Earlier Trials Failed
Three structural problems plagued the failed trials:
Wrong patient population. Early trials enrolled patients with mild-to-moderate Alzheimer's dementia. By that stage, neuronal death is so extensive that removing plaques is analogous to unclogging a drain after the pipes have burst. Amyloid needs to be cleared during the preclinical or early mild-cognitive-impairment (MCI) phase.
Wrong endpoints. Cognitive scales like ADAS-Cog were designed to detect large, rapid changes. They lacked the statistical sensitivity to measure the modest, gradual slowing that a disease-modifying therapy might produce over 18 months.
Biology underestimated. Amyloid clearance is necessary but not sufficient. Tau propagation, neuroinflammation, synaptic loss, and vascular dysfunction are co-drivers that continue even when plaques are removed.
The 2023 CLARITY AD trial of lecanemab corrected for all three problems: it enrolled early-stage patients confirmed by amyloid PET or CSF biomarkers, used the CDR-SB (Clinical Dementia Rating – Sum of Boxes) as its primary endpoint, and ran for 18 months with a large enough sample (1,795 participants) to detect modest effects. The result — a 27% slowing of clinical decline — was statistically significant and broadly replicated (van Dyck et al., 2023, NEJM).
The amyloid hypothesis, after 30 years of controversy, has its first clinical vindication. It remains incomplete — tau, inflammation, and vascular health matter — but amyloid is causal in a meaningful sense.
2023–2026: The First Disease-Modifying Drugs
The approval of lecanemab (Leqembi) by the FDA in July 2023 and donanemab (Kisunla) in July 2024 marked a genuine turning point. Both are monoclonal antibodies that bind to and clear amyloid plaques from the brain via intravenous infusion. They are the first drugs ever shown to slow Alzheimer's disease progression, not merely manage symptoms like memory aids do.
| Drug (Brand) | Target | Efficacy (CDR-SB slowing) | Dosing | Approx. Annual Cost (US) | Key Side Effect |
|---|---|---|---|---|---|
| Lecanemab (Leqembi) | Amyloid-beta protofibrils | 27% | IV infusion every 2 weeks | ~$26,500 | ARIA-E, ARIA-H |
| Donanemab (Kisunla) | N3pG amyloid (truncated form) | 35% (low/medium tau group) | IV infusion monthly | ~$32,000 | ARIA-E, ARIA-H |
| Aducanumab (Aduhelm) | Amyloid aggregates | Contested (withdrawn 2024) | IV infusion monthly | Withdrawn | ARIA-E, ARIA-H |
| Donepezil (Aricept) | Acetylcholinesterase (symptomatic) | Symptomatic only | Oral, daily | ~$300 | GI upset, bradycardia |
| Memantine (Namenda) | NMDA receptor (symptomatic) | Symptomatic only | Oral, daily | ~$400 | Dizziness, confusion |
Approved Alzheimer's treatments as of mid-2026. Disease-modifying = slows progression. Symptomatic = manages but does not alter disease course. Efficacy figures from pivotal phase 3 trials (van Dyck et al., 2023; Sims et al., 2023, NEJM).
ARIA-E — amyloid-related imaging abnormalities with edema; brain swelling visible on MRI that occurs in a subset of patients receiving anti-amyloid antibodies, ranging from asymptomatic to serious. ARIA-H — amyloid-related imaging abnormalities with microhemorrhages; small bleeds in brain tissue, generally asymptomatic but requiring monitoring.
ARIA is the most significant safety concern with both approved drugs. In the CLARITY AD trial, 21.3% of lecanemab-treated patients developed ARIA-E, though most cases were asymptomatic and resolved without intervention (van Dyck et al., 2023). Patients on blood thinners and those carrying two copies of the APOE4 gene face substantially higher risk.
The clinical reality is that these drugs are a meaningful but modest step. A 27–35% slowing of decline is not a cure — a patient who would have reached moderate dementia in 36 months might now reach it in 49 months. The benefit is real, the risk is real, and the decision to treat requires careful patient selection by a specialist.
Medicare coverage for both drugs was confirmed in 2024 for patients enrolled in approved registries, making access broader but still logistically challenging due to the need for PET imaging, infusion center infrastructure, and regular MRI monitoring.
Blood Biomarkers — Diagnosis Is Finally Getting Easier
For decades, confirming Alzheimer's pathology required either a lumbar puncture (spinal tap) to measure amyloid and tau in cerebrospinal fluid, or a costly PET scan using radioactive tracers. Neither was practical at scale. The result: most patients were diagnosed clinically — by symptoms alone — which is imprecise and often late.
Blood biomarker — a measurable biological substance in blood plasma that reflects a specific pathological process in the body; in Alzheimer's, blood biomarkers can indicate amyloid plaques, tau tangles, or neurodegeneration without invasive procedures.
Between 2023 and 2026, plasma biomarkers have transformed early detection:
- Plasma p-tau217 (phosphorylated tau at threonine 217) — now validated in multiple large studies as a highly accurate blood test for Alzheimer's pathology. A 2023 study in JAMA (Hansson et al.) showed plasma p-tau217 had 90%+ accuracy for distinguishing Alzheimer's from other dementias — comparable to CSF tests and PET imaging, at a fraction of the cost.
- Plasma amyloid-beta 42/40 ratio — measures the relative abundance of two amyloid fragments; a lower ratio indicates amyloid accumulation in the brain. Validated in the AHEAD 3–45 trial cohort.
- GFAP (glial fibrillary acidic protein) — a marker of astrocyte activation and neuroinflammation, elevated years before symptom onset.
- NfL (neurofilament light chain) — a general marker of neurodegeneration, elevated in Alzheimer's and other neurodegenerative diseases.
The FDA cleared the first blood-based Alzheimer's test for clinical use in 2024 (ALZpath p-tau217). By 2026, several CLIA-certified labs offer plasma p-tau217 testing, with results available within days at costs of $200–$500 — compared to $3,000–$5,000 for amyloid PET. This shift means primary care physicians can now initiate a diagnostic workup with a blood test before referring to a specialist, dramatically compressing the diagnostic timeline.
For patients who screen positive on blood tests and are eligible for anti-amyloid therapy, confirmatory PET or CSF testing is still recommended before starting treatment. But the blood test is now the rational first step, replacing the "wait and see" approach that delayed diagnosis by an average of 2.8 years in prior decades (Alzheimer's Association, 2024).
The 14 Modifiable Risk Factors (Lancet Commission 2024)
Not all Alzheimer's risk is biological fate. The 2024 Lancet Commission on Dementia Prevention, Intervention, and Care — the field's most authoritative population-level analysis — identified 14 modifiable risk factors that together account for approximately 45% of all dementia cases worldwide (Livingston et al., 2024, The Lancet). Eliminating or reducing these risk factors would, in theory, prevent nearly half of all cases.
This is not speculation. It is a population-attributable risk calculation: if these factors were absent from the population, 45% of dementia cases would not occur. Individual risk reduction varies, but the collective implication is significant.
| Risk Factor | Type | Estimated PAR (%) | Life Stage | Intervention |
|---|---|---|---|---|
| Lower educational attainment | Non-modifiable (partially) | 5% | Early life | Promote formal education, cognitive engagement |
| Hearing loss | Modifiable | 7% | Midlife | Hearing aids, noise protection |
| Depression | Modifiable | 3% | Midlife/Late | Treatment, therapy, social support |
| Social isolation | Modifiable | 5% | Late life | Community engagement, reducing loneliness |
| Physical inactivity | Modifiable | 2% | Midlife/Late | 150+ min/week moderate aerobic activity |
| Diabetes | Modifiable | 2% | Midlife/Late | Blood sugar management, diet |
| Obesity | Modifiable | 1% | Midlife | Healthy weight maintenance |
| Hypertension | Modifiable | 2% | Midlife | Blood pressure control, medication |
| Excessive alcohol (>21 units/week) | Modifiable | 1% | All stages | Reduction to low-risk levels |
| Traumatic brain injury | Modifiable | 3% | All stages | Helmet use, fall prevention |
| Air pollution | Modifiable | 3% | All stages | Reduce exposure; environmental policy |
| Smoking | Modifiable | 2% | All stages | Cessation |
| High LDL cholesterol | Modifiable | 7% | Midlife | Diet, statins if indicated |
| Vision loss (untreated) | Modifiable | 2% | Late life | Corrective lenses, cataract surgery |
Modifiable risk factors for dementia from the Lancet Commission on Dementia Prevention 2024 (Livingston et al., 2024). PAR = population-attributable risk. The 14 factors sum to ~45% of dementia cases. APOE4 genotype and age are non-modifiable and not included in PAR calculation.
APOE4 — a variant of the apolipoprotein E gene on chromosome 19. Carrying one copy of APOE4 increases Alzheimer's risk 3–4 times; carrying two copies increases risk 8–12 times. APOE4 is the single strongest known genetic risk factor for late-onset Alzheimer's, present in roughly 25% of the population. However, APOE4 is not deterministic — most APOE4 carriers do not develop Alzheimer's, and many Alzheimer's patients do not carry APOE4.
Hearing loss stands out as the single largest modifiable risk factor (7% PAR), yet it is one of the most undertreated conditions globally. A 2023 randomized trial (the ACHIEVE study, published in The Lancet) found that hearing intervention significantly reduced cognitive decline in older adults at elevated risk — the first trial to show cognitive benefit from hearing aid use in a high-risk population.
The chronic stress-cortisol pathway is also increasingly implicated. Prolonged cortisol elevation from chronic stress damages the hippocampus — the brain's memory-formation center and the first region Alzheimer's destroys. Managing stress is not a soft recommendation; it has measurable neurobiological consequences relevant to dementia risk.
Sleep deserves special mention. While the Lancet 2024 update did not list sleep as a standalone factor with a calculated PAR (the evidence base was not yet sufficient for formal inclusion), the mechanistic case is compelling: during deep sleep, the glymphatic system — a network of cerebrospinal fluid channels — flushes amyloid-beta from the brain. Poor sleep quality, particularly disrupted slow-wave sleep, reduces glymphatic clearance and is associated with higher amyloid burden in longitudinal studies (Ju et al., 2017, Brain). The science of why we sleep has direct bearing on dementia prevention.
What We Still Cannot Do
Progress has been real, but it is important not to overstate it. As of 2026, there is no cure for Alzheimer's. There is no way to reverse neuronal death that has already occurred. And there are significant gaps in the scientific understanding of the disease.
Tau-Targeted Therapies Have Not Arrived
Despite tau's stronger correlation with symptom severity than amyloid, no anti-tau therapy has yet reached approval. Several anti-tau antibodies — including semorinemab, gosuranemab, and tilavonemab — failed phase 2 and 3 trials. The problem may be that tau spreads through the brain along neural circuits in a prion-like manner; by the time it is measurable, it has already propagated widely. Earlier intervention or different mechanisms (such as tau aggregation inhibitors or small-molecule approaches) are in phase 2 trials as of 2026.
The Heterogeneity Problem
Alzheimer's disease is not one disease. Genetic studies reveal distinct biological subtypes — some driven primarily by amyloid, others by tau, others by neuroinflammation or synaptic dysfunction — that likely require different treatments. Clinical trials that treat "Alzheimer's" as a single entity may be diluting signal. Precision medicine approaches, stratifying patients by biomarker profile and genetic risk before enrollment, are gaining traction but have not yet yielded approved differentiated therapies.
Access and Equity Are Failing
Even the therapies that exist reach relatively few patients. Anti-amyloid antibodies require PET imaging or CSF testing for confirmation (adding $3,000–$5,000 to upfront cost), infusion center infrastructure, and MRI monitoring every 3 months. This infrastructure exists primarily at academic medical centers. Rural patients, patients in low-income countries, and those without Medicare coverage face substantial barriers. Approximately 70% of the global dementia burden is in low- and middle-income countries, where the new therapies are effectively unavailable (WHO, 2024).
Prevention Trials Are Just Starting
The most important unanswered question in Alzheimer's prevention is whether treating amyloid in asymptomatic APOE4 homozygotes or genetically high-risk individuals — before any symptoms — prevents dementia. The A4 trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer's) and the Generation Program are addressing this, but results are years away. The answer will determine whether Alzheimer's can eventually be treated like cardiovascular disease — with preventive intervention long before symptoms appear.
The aging biology of the brain interacts with Alzheimer's pathology in ways that are still being untangled. Normal aging reduces glymphatic efficiency, increases neuroinflammation, and erodes synaptic density — all of which lower the threshold at which Alzheimer's pathology causes clinical symptoms.
What to Actually Do Today
The following is general health information, not personalized medical advice. Decisions about testing, diagnosis, and treatment must be made with a qualified physician.
Based on the current evidence base, the lifestyle factors with the strongest support for protecting cognitive health in the long term are:
Sleep quality. Prioritize 7–9 hours of sleep per night. Untreated sleep apnea is associated with up to a 2.6-fold increased Alzheimer's risk (Osorio et al., 2015, Journal of Alzheimer's Disease) and should be evaluated and treated. Slow-wave sleep is when glymphatic clearance peaks.
Aerobic exercise. The most consistently evidence-backed behavioral intervention for brain health. 150 minutes per week of moderate-intensity aerobic activity (brisk walking, swimming, cycling) reduces dementia risk by approximately 28% in population studies (Iso-Markku et al., 2022, British Journal of Sports Medicine).
Hearing health. If you use hearing aids or have untreated hearing loss, the ACHIEVE trial (2023) provides the strongest controlled evidence to date that correcting hearing loss reduces cognitive decline in at-risk adults. Get hearing tested regularly after age 50.
Cardiovascular health. Blood pressure, blood sugar, and cholesterol are all modifiable Alzheimer's risk factors with established interventions. The brain's vascular health is inseparable from its cognitive health; atherosclerosis and hypertension damage small cerebral vessels and accelerate the transition from preclinical Alzheimer's to dementia.
Cognitive and social engagement. Formal education, language learning, reading, and social connection build what researchers call "cognitive reserve" — the brain's functional resilience that delays symptom onset even as underlying pathology accumulates. A highly educated person may have the same amyloid burden as someone with less education but show fewer symptoms, because they have more synaptic redundancy to draw on.
Know your family history. If you have a first-degree relative (parent or sibling) with Alzheimer's, discuss your risk profile with your physician. Genetic testing for APOE4 is available, but its interpretation is nuanced — it indicates risk, not destiny — and should be done in the context of genetic counseling.
The relationship between lifestyle factors and aging biology and longevity is increasingly well understood. The same interventions that reduce cardiovascular disease — diet quality, physical activity, sleep, stress management — appear to reduce Alzheimer's risk through overlapping mechanisms.
If you notice persistent memory changes in yourself or a family member — particularly new difficulty remembering recent events (as opposed to occasional forgetting of names or words) — the appropriate next step is a visit to a primary care physician, not a specialist. A blood test for plasma p-tau217 can now initiate the diagnostic workup at the primary care level.
Frequently Asked Questions
Q: Can Alzheimer's disease be prevented? A: No single intervention can guarantee prevention, but approximately 45% of dementia cases are linked to 14 modifiable risk factors (Lancet Commission, 2024). Addressing hearing loss, maintaining cardiovascular health, staying physically active, sleeping adequately, and remaining socially engaged substantially reduce population-level risk. Prevention trials in genetically high-risk, asymptomatic individuals are underway but have not yet produced results.
Q: Is APOE4 genetic status a destiny for Alzheimer's? A: No. Carrying two copies of APOE4 raises lifetime Alzheimer's risk to roughly 40–65% compared to 10–12% in the general population — significantly elevated, but not deterministic. Many APOE4 homozygotes never develop Alzheimer's, and many Alzheimer's patients have no copies of APOE4. Lifestyle factors appear to modify even genetic risk; APOE4 carriers who exercise regularly and maintain cardiovascular health have meaningfully lower risk than sedentary APOE4 carriers.
Q: When should someone get tested for Alzheimer's? A: Routine screening is not currently recommended for asymptomatic adults without risk factors. Testing is appropriate when a person or their family notices persistent, progressive cognitive changes — particularly difficulty forming new memories, getting lost in familiar places, or struggling with previously routine tasks. Plasma p-tau217 blood testing is now available through primary care referral and is a reasonable starting point.
Q: Do the new Alzheimer's drugs (Leqembi, Kisunla) work for everyone? A: They are approved for adults with early-stage Alzheimer's disease — specifically mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia — confirmed by amyloid biomarker testing. They are not appropriate for moderate or severe dementia. Patients with certain genetic profiles (APOE4 homozygotes) face higher ARIA risk and require especially careful evaluation. Both drugs slow decline rather than reverse it.
Q: What is ARIA and how dangerous is it? A: ARIA (amyloid-related imaging abnormalities) is a brain swelling or microbleeding reaction to anti-amyloid antibodies. It occurs in 21–37% of patients in clinical trials, but the majority of ARIA cases are asymptomatic and detected only on routine MRI monitoring. Serious, symptomatic ARIA occurs in approximately 2–3% of patients. Risk is higher in APOE4 carriers and those on anticoagulant medications.
Q: Are there any Alzheimer's drugs in development beyond amyloid? A: Yes. Active areas include anti-tau antibodies and aggregation inhibitors, neuroinflammation modulators targeting microglia (such as TREM2 pathway drugs), synaptic strengthening agents, GLP-1 agonists (semaglutide is in phase 3 trials for Alzheimer's as of 2026), and senolytic therapies targeting senescent cells in the brain. No tau-targeted therapy has reached approval yet.
Q: What is the difference between Alzheimer's disease and dementia? A: Dementia is an umbrella term for a syndrome of cognitive decline severe enough to interfere with daily function. Alzheimer's disease is the most common cause of dementia (60–70% of cases), but other causes include vascular dementia, Lewy body dementia, frontotemporal dementia, and others. Not all dementia is Alzheimer's, and the distinction matters for treatment.
Q: Can a blood test diagnose Alzheimer's disease? A: Blood tests — particularly plasma p-tau217 — can now detect Alzheimer's pathology (amyloid and tau changes in the brain) with accuracy comparable to PET scans and spinal fluid tests, at far lower cost. However, a positive blood test is not a diagnosis of Alzheimer's disease; it indicates biological changes consistent with Alzheimer's pathology. Clinical diagnosis also requires cognitive assessment and, typically, confirmatory imaging or CSF testing before starting disease-modifying treatment.
Sources
van Dyck, C. H. et al. (2023). Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
Sims, J. R. et al. (2023). Donanemab in Early Symptomatic Alzheimer's Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA, 330(6), 512–527. https://doi.org/10.1001/jama.2023.13239
Livingston, G. et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572–628. https://doi.org/10.1016/S0140-6736(24)01296-0
Hansson, O. et al. (2023). Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nature Aging, 3, 506–519. https://doi.org/10.1038/s43587-023-00408-4
World Health Organization (2024). Dementia Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/dementia
Alzheimer's Association (2024). 2024 Alzheimer's Disease Facts and Figures. https://www.alz.org/alzheimers-dementia/facts-figures
Hardy, J. & Higgins, G. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science, 256(5054), 184–185.
Cummings, J. et al. (2019). Alzheimer's disease drug development pipeline: 2019. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 5, 272–293.
Iso-Markku, P. et al. (2022). Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. British Journal of Sports Medicine, 56(12), 701–709.
Osorio, R. S. et al. (2015). Sleep-disordered breathing advances cognitive decline in the elderly. Journal of Alzheimer's Disease, 44(1), 179–191.
Ju, Y. E. S. et al. (2017). Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain, 140(8), 2104–2111.
Follow new articles
Add SciHub101 to your feed reader to see new science and technology stories.
About the Author
SciHub101 is an independent science and technology publication founded and edited by Buğra Sözeri, a software engineer and app developer based in Türkiye. AI tools assist with drafting and research. Source documentation in the existing archive is uneven, and articles are being reviewed and corrected. The Editorial Team byline identifies editorial responsibility; it does not certify specialist or independent human review. Where we compare products, anything built by our own team is labelled as such — see the editorial guidelines and About page for how corrections and disclosures work.
Related Articles

CRISPR Gene Editing in 2026 — What's Been Cured, What's Coming, What's Real vs Hype
CRISPR has produced its first approved cures for sickle cell disease and beta-thalassemia. Here's what's real, what's coming, and what remains hype in 2026.

Countries with the Most Doctors Per Capita (Physicians Per 1,000 People Ranked)
Cuba has 9.54 physicians per 1,000 people — the highest doctor-to-population ratio of any large nation on earth. That is nearly three times the OECD average of 3.7, and more than six times the WHO's minimum recommended threshold of 1.5. Behind Cuba sit Monaco, Greece, Belgium, and Lithuania in a top five dominated by an unexpected mix of a Caribbean socialist state and small European nations.

Alzheimer's Disease: The Biology Behind the Decline
How amyloid plaques, tau tangles, and neuronal death drive Alzheimer's—plus new blood tests, FDA-approved drugs, and prevention evidence.

Complete Biology Guide 2026 — How Life Works
The complete guide to biology in 2026: cells and genetics, evolution, the human body, neuroscience, disease, immune systems, and the future of genetic engineering.

How the Gut Microbiome Affects Mental Health
Your gut microbiome influences your brain through the vagus nerve, immune signaling, and microbial chemistry. Here is what the mechanisms, the animal work, and the human trials actually show, and where the evidence stops.

The Science of Sleep: What Happens in the Brain During REM Sleep
Sleep is not a passive shutdown but an active state of brain and body reorganization. During an 8-hour sleep cycle, humans alternate between non-REM (NREM) sleep—characterized by slow theta waves, reduced muscle tone, and energy conservation—and REM (rapid eye movement) sleep, when the brain shows activity patterns similar to wakefulness, the eyes move rapidly beneath closed eyelids, and skeletal muscles are paralyzed except for the diaphragm. REM sleep makes up approximately 20–25 percent of sleep in adults and is the stage where most vivid dreaming occurs. The neuroscience of REM reveals that memory consolidation (particularly emotional and procedural memories), creativity processing, and amygdala-driven emotion regulation all occur during this stage. The glymphatic system—a network of fluid pathways that clear metabolic waste from the brain during sleep—becomes most active during deep NREM sleep, not REM. This article explains the neuroscience of REM sleep, the discovery of the glymphatic system, and why sleep is essential to brain health.